Bank Julius Baer & Co. Ltd Zurich Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Bank Julius Baer & Co. Ltd Zurich lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,632 shares of the medical research company’s stock after selling 720 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in IQVIA were worth $9,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of IQVIA by 9.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,610 shares of the medical research company’s stock worth $1,067,000 after purchasing an additional 415 shares during the last quarter. GAMMA Investing LLC acquired a new stake in IQVIA during the fourth quarter valued at $60,000. Marks Group Wealth Management Inc grew its position in IQVIA by 0.8% during the fourth quarter. Marks Group Wealth Management Inc now owns 30,807 shares of the medical research company’s stock valued at $7,128,000 after buying an additional 259 shares during the period. Aspire Private Capital LLC grew its position in IQVIA by 8.6% during the fourth quarter. Aspire Private Capital LLC now owns 2,957 shares of the medical research company’s stock valued at $684,000 after buying an additional 235 shares during the period. Finally, CWM LLC grew its position in IQVIA by 5.5% during the fourth quarter. CWM LLC now owns 3,980 shares of the medical research company’s stock valued at $921,000 after buying an additional 207 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. Evercore ISI raised their price target on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. UBS Group lifted their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Finally, Robert W. Baird raised their price target on shares of IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Stock Up 0.4 %

NYSE IQV traded up $0.90 on Friday, hitting $234.88. 635,995 shares of the stock were exchanged, compared to its average volume of 970,046. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a market cap of $42.63 billion, a PE ratio of 32.22, a PEG ratio of 2.33 and a beta of 1.50. The company has a 50-day moving average price of $245.35 and a 200-day moving average price of $222.77.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the previous year, the business posted $2.54 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,285 shares of company stock worth $10,331,003. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.